Browsing Tag
Andreessen Horowitz
35 posts
U.S. Navy places up to $200m Blackbeard production order with Castelion
The U.S. Navy has placed a production delivery order worth up to $200 million for Castelion’s Blackbeard hypersonic weapon, advancing the programme beyond early operational prototypes as the startup deploys fresh private capital into manufacturing scale.
Heron Power secures $60m credit facility as Factory One moves toward production
Heron Power has added a $60 million credit facility after its $140 million Series B as it converts a 286,000-square-foot California warehouse into a high-volume factory for 5 MW medium-voltage power systems.
Thyme Care crosses $2bn valuation as $7bn oncology platform expands into new businesses
Thyme Care has secured more than $125 million from Morgan Health, Humana, CVS Health Ventures and other investors at a valuation above $2 billion. The company is already profitable, reaches 10.5 million people and manages more than $7 billion of oncology spending. Its next move is more ambitious: turning the cancer-care platform into a parent company that can attack drug costs, biosimilar adoption and clinical-trial access.
Sirius brings real-time AI decisioning to subscription cancellations after a16z Speedrun
Sirius has emerged from Andreessen Horowitz’s a16z Speedrun with an AI platform that decides how to respond when subscribers try to leave, while early traction points to a potentially larger autonomous retention category.
River AI’s $1.1bn war chest: Can a four-month-old neolab crack enterprise AI?
Igor Babuschkin's River AI has landed $1.1 billion with Nvidia and AMD Ventures backing, squeezing closed-source labs on enterprise fine-tuning economics.
Volta Infra hits $2.4bn valuation as AI cloud buildout tests Europe’s compute ambitions
Volta Infra has reportedly raised funding at a $2.4 billion valuation and secured a $10 billion AI infrastructure agreement, but investors must decide whether Europe’s AI cloud capacity can scale fast enough to justify the hype.
Braveheart Bio IPO targets $1.2bn valuation as HCM drug race heats up
Braveheart Bio is seeking up to $318.8 million in its Nasdaq IPO, but investors must decide whether its cardiac myosin inhibitor can compete in an increasingly crowded hypertrophic cardiomyopathy market.
Travis Kalanick’s Atoms secures $1.7bn to scale physical AI businesses
Atoms has secured $1.7 billion in debt and equity financing led by Andreessen Horowitz, giving Travis Kalanick’s industrial AI venture fresh capital to automate mining, food production, construction and transport.
Anduril targets $100bn valuation as defence-tech funding tests public-market reality
Anduril Industries is reportedly in talks for a fresh funding round at a valuation near $100 billion, turning the defence-technology startup into a private-market challenger to established military contractors.
Etched raises $300m as $10.3bn valuation tests AI inference chip economics
Etched’s $300 million Series C gives the AI chip startup fresh capital to scale its Sohu inference systems, but the valuation depends on whether specialised hardware can break NVIDIA’s grip on data-centre computing.